Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients
Jesse W. Keller(UCSF Helen Diller Family Comprehensive Cancer Center), Rebecca L. Olin(University of California, San Francisco), Jeffrey L. Wolf(City College of San Francisco), Weiyun Z. Ai(City College of San Francisco), Lawrence D. Kaplan(UCSF Helen Diller Family Comprehensive Cancer Center), Lloyd E. Damon(University of California, San Francisco), Charalambos Andreadis(University of California, San Francisco), Thomas Martin(University of California, San Francisco), Catherine C. Smith(University of California, San Francisco), Jimmy Hwang(University of California, San Francisco), Karin Gaensler(University of California, San Francisco), Jeffrey M. Venstrom(Foundation Medicine (United States))
Cited by 28
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782